Analysts Set Lucid Diagnostics Inc. (NASDAQ:LUCD) Price Target at $3.55

Shares of Lucid Diagnostics Inc. (NASDAQ:LUCD) have received a consensus recommendation of “Buy” from the five analysts that are presently covering the firm, MarketBeat Ratings reports. Four research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $3.55.

Several analysts have issued reports on LUCD shares. Wall Street Zen downgraded shares of Lucid Diagnostics from a “hold” rating to a “sell” rating in a research note on Thursday, May 22nd. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $2.00 target price on shares of Lucid Diagnostics in a research report on Thursday, May 15th. Needham & Company LLC reiterated a “buy” rating and issued a $3.00 target price on shares of Lucid Diagnostics in a report on Wednesday, May 14th. BTIG Research set a $2.00 target price on Lucid Diagnostics in a report on Tuesday, March 25th. Finally, Ascendiant Capital Markets lifted their price objective on Lucid Diagnostics from $7.50 to $7.75 and gave the company a “buy” rating in a report on Friday, June 6th.

Lucid Diagnostics Price Performance

Shares of NASDAQ LUCD opened at $1.26 on Monday. The company has a market cap of $136.32 million, a P/E ratio of -0.94 and a beta of 1.31. Lucid Diagnostics has a 1 year low of $0.68 and a 1 year high of $1.80. The firm has a 50-day simple moving average of $1.28 and a two-hundred day simple moving average of $1.18.

Hedge Funds Weigh In On Lucid Diagnostics

Large investors have recently made changes to their positions in the business. Berkshire Asset Management LLC PA acquired a new position in shares of Lucid Diagnostics during the first quarter worth $30,000. Northwestern Mutual Wealth Management Co. acquired a new position in shares of Lucid Diagnostics during the first quarter worth $37,000. Cubist Systematic Strategies LLC purchased a new stake in shares of Lucid Diagnostics during the first quarter valued at $39,000. LPL Financial LLC grew its holdings in shares of Lucid Diagnostics by 29.1% during the fourth quarter. LPL Financial LLC now owns 53,391 shares of the company’s stock valued at $44,000 after buying an additional 12,035 shares during the last quarter. Finally, Sunbelt Securities Inc. purchased a new stake in shares of Lucid Diagnostics during the fourth quarter valued at $67,000. 74.01% of the stock is owned by institutional investors and hedge funds.

Lucid Diagnostics Company Profile

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.